Silver Book Fact

Patients with vertebral fractures who underwent kyphoplasty, a procedure that stabilizes fractures of the spine, were found in one study to have reduced pain, fewer new fractures, and less healthcare utilization for at least 12 months.

Grafe, Ingo A., Katharina Da Fronseca, Jochen Hillmeier, Peter-Jürgen Meeder, Martin Libicher, Gerd Nöldge, Hubert Bardenheuer, Walter Pyerin, Linus Basler, Christel Weiss, Rod S. Taylor, Peter Nawroth, and Christian Kasperk. Reduction of Pain and Fracture Incidence After Kyphoplasty: 1-year outcomes of a prospective controlled trial of patients with primary osteoporosis. Osteoporos Int. 2005; 16(12): 2005-12. http://www.springerlink.com/content/q235u1m804u08551/?p=34936217d13e479297297d5ff7202c45&pi=72

Reference

Title
Reduction of Pain and Fracture Incidence After Kyphoplasty: 1-year outcomes of a prospective controlled trial of patients with primary osteoporosis
Publication
Osteoporos Int
Publication Date
2005
Authors
Grafe, Ingo A., Katharina Da Fronseca, Jochen Hillmeier, Peter-Jürgen Meeder, Martin Libicher, Gerd Nöldge, Hubert Bardenheuer, Walter Pyerin, Linus Basler, Christel Weiss, Rod S. Taylor, Peter Nawroth, and Christian Kasperk
Volume & Issue
Volume 16, Issue 12
Pages
2005-12
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is…  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…